10397-13-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(4,6-Dichloropyrimidin-2-yl)morpholine is used as a key intermediate in the synthesis of pharmaceutical drugs. Its unique structure and functional groups contribute to the development of new therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(4,6-Dichloropyrimidin-2-yl)morpholine serves as an essential building block for the creation of fungicides and herbicides. Its chemical properties allow for the design of effective crop protection products that help control pests and diseases in agriculture.
Used in Organic Synthesis:
4-(4,6-Dichloropyrimidin-2-yl)morpholine is utilized as a versatile building block in the synthesis of complex organic compounds. Its reactivity and functional groups enable the formation of a wide range of molecules with diverse applications in various industries, including materials science, chemical research, and specialty chemicals.

InChI:InChI=1/C8H9Cl2N3O/c9-6-5-7(10)12-8(11-6)13-1-3-14-4-2-13/h5H,1-4H2

Upstream product

• 110-91-8 morpholine 
• 3764-01-0 2,4,6-trichloropyrimidine 
• 157415-17-3 Morpholine-4-carboxamidine; hydrobromide 
• 17238-66-3 morpholine-4-carboxamidine 
• 24193-00-8 2-(morpholin-4-yl)pyrimidine-4,6-diol 
• 50596-83-3 2-morpholin-4-yl-1H-pyrimidine-4,6-dione 
• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 
• 56-05-3 2-Amino-4,6-dichloropyrimidine 

Downstream Products

• 544693-01-8 4-(6-chloro-2-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine 
• 887402-10-0 6-[2-(pyridin-2-yl)-ethoxy]-2-chloro-4-(morpholin-4-yl)-pyrimidine 
• 887402-09-7 4-[2-(pyridin-2-yl)-ethoxy]-6-chloro-2-(morpholin-4-yl)-pyrimidine 
• 1333108-16-9 1-cyclopropyl-3-(4-(2-morpholino-6-(pyridin-3-yl)pyrimidin-4-yl)phenyl)urea 
• 1453082-78-4 (4S,5S)-4-(((tert-butyldiphenylsilanyl)oxy)methyl)-3-(6-chloro-2-(morpholin-4-yl)pyrimidin-4-yl)-5-methyloxazolidin-2-one 
• 1453082-84-2 (S)-3-(2'-amino-2-(morpholin-4-yl)-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-(((tert-butyldiphenylsilanyl)oxy)methyl)-[1,3]oxazinan-2-one 
• 1453082-85-3 (S)-4-(((tert-butyldiphenylsilanyl)oxy)methyl)-3-(6-chloro-2-(morpholin-4-yl)pyrimidin-4-yl)-[1,3]oxazinan-2-one 
• 1453082-67-1 (S)-3-(2'-amino-2-(morpholin-4-yl)-4'-(trifluoromethyl)-[4,5']bipyrimidinyl-6-yl)-4-(((tertbutyldiphenylsilanyl)oxy)methyl)-5,5-dimethyloxazolidin-2-one 
• 1453082-68-2 (S)-4-(((tert-butyldiphenylsilanyl)oxy)methyl)-3-(6-chloro-2-(morpholin-4-yl)-pyrimidin-4-yl)-5,5-dimethyloxazolidin-2-one 
• 1609551-31-6 (4S,5S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(6-chloro-2-morpholinopyrimidin-4-yl)-5-(4-methoxyphenyl)oxazolidin-2-one 
• 1013402-34-0 N-[2-[(6-chloro-2-morpholin-4-yl-pyrimidin-4-yl)amino]phenyl]-2,2,2-trifluoro-acetamide 

Relevant academic research and scientific papers

Regioselective 2-Amination of Polychloropyrimidines

The regioselective amination of substituted di- and trichloropyrimidines affording the 2-substituted products is reported. While aryl- and heteroarylamines require the use of a dialkylbiarylphosphine-derived palladium catalyst for high efficiency, more nucleophilic dialkylamines produce 2-aminopyrimidines under noncatalyzed SNAr conditions. The key is the use of 5-trimethylsilyl-2,4-dichloropyrimidine as a surrogate for the parent dichloropyrimidine. For more challenging cases, the 2-chloro-4-thiomethoxy analogues were prepared and exclusively afford the desired 2-aminated-4-thiomethoxypyrimidine products.

Synthesis and PI3 kinase inhibition activity of some novel trisubstituted morpholinopyrimidines

A number of new substituted morpholinopyrimidines were prepared utilizing sequential nucleophilic aromatic substitution and cross-coupling reactions. One of the disubstituted pyrimidines was converted into two trisubstituted compounds which were screened as PI3K inhibitors relative to the well-characterized PI3K inhibitor ZSTK474, and were found to be 1.5–3-times more potent. A leucine linker was attached to the most active inhibitor since it would remain on any peptide-containing prodrug after cleavage by prostate-specific antigen, and it did not prevent inhibition of AKT phosphorylation and hence the inhibition of PI3K by the modified inhibitor.

Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy

Concomitant inhibition of PARP and PI3K pathways has been recognized as a promising strategy for cancer therapy, which may expand the clinical utility of PARP inhibitors. Herein, we report the discovery of dual PARP/PI3K inhibitors that merge the pharmaco

INHIBITORS OF RAF KINASES

Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

PARP-1 and PI3K double-target inhibitor containing benzofuran

The invention relates to the field of medicinal chemistry, in particular to a PARP-1 and PI3K double-target inhibitor containing a benzofuran structure (I) (the formula I is shown in the description),a preparation method and a medicine composition containing thereof. Proved by a pharmacodynamic test, the PARP-1 and PI3K double-target inhibitor has the anti-tumor effect.

PARP (poly-ADP-ribose polymerase)-1 and PI3K (phosphatidylinositol-3-kinase) dual target inhibitors containing phthalazine-1(2H)-ketone structure

The invention relates to the field of medicinal chemistry, and specifically relates to a kind of PARP (poly-ADP-ribose polymerase)-1 and PI3K (phosphatidylinositol-3-kinase) dual target inhibitors (I)containing phthalazine-1(2H)-ketone and triazine or pyrimidine structures, preparation methods of the inhibitors, as well as pharmaceutical compositions containing compounds. It is proved, by pharmacodynamic tests, that the compounds involved in the invention have anti-tumor effects. The dual target inhibitors (I) are shown in the description.

PI3K INHIBITOR, AND PHARMACEUTICALLY ACCEPTABLE SALT, POLYCRYSTALLINE FORM, AND APPLICATION THEREOF

The present invention relates to a PI3K inhibitor, and a pharmaceutically acceptable salt, polycrystalline form, and application thereof. The invention specifically provides a polycrystalline form of 4-chloro-5-(6-(1-(methylsulfonyl)cyclopropyl)-2-morpholinopyrimidin-4-yl)pyridin-2-amine, a pharmaceutically acceptable salt thereof, or a polycrystalline form of the salt. The invention further discloses a pharmaceutical composition comprising the inhibitor and an application of the pharmaceutical composition.

2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF

Disclosed is a 2-morpholin-4,6-disubstituted pyrimidine derivative as shown in formula (I) below, and a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, and a pharmaceutical composition thereof and a use thereof, wherein the definition of each group is as shown in the description. The compound has a PI3K kinase inhibition activity, and has a relatively high inhibitive ability and a low cytotoxicity against PIK3CA mutant breast cancer cell strains T47D and MCF-7.

TREATMENT OF SKIN LESIONS

The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1 X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1alkoxyC1-C3alkyl, CN, or C(O)O-C1-C2alkyl; or R3 and R4 form together a bivalent residue -R5R6- selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue-R8R9- selected from Ci-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2- or -O-CH2CH2-O-; with the proviso that at least one of R1 and R2is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in the prevention or treatment of a skin lesion in a subject.

TREATMENT OF NEUROLOGICAL DISORDERS

The present invention is relates to a compound of formula (I), wherein X1, X2 andX3 are, independently of each other, N or CH; with the proviso that at least two of X1X2andX3 areN; Y is N or CH; R1 and R2 are independently of each other (iii)a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fhioroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(0)0-C1- C2alkyl; or R3 and R4 form together a bivalent residue -R5R6- selected from Ci-C3alkylene optionally substituted with 1 to 4 F, -CH2-0-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); or (iv) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence Ci-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1- C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue -R8R9- selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-0-CH2- or -O- CH2CH2-0-; with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in the prevention or treatment of a neurological disorder in a subject.